GrayBug's Jeffrey Cleland To Present At Glaucoma 360 On January 29
BALTIMORE, MD--(Marketwired - Jan 29, 2016) - GrayBug, Inc., a venture-stage pharmaceutical company developing microparticle controlled release drug delivery technologies for the treatment of ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, announced that Jeffrey L. Cleland, PhD, GrayBug Interim Chief Executive Officer, will present an overview of company research at a day-long review of the latest innovations in the ophthalmic industry on Friday, January 29, during the Glaucoma 360 meeting in San Francisco. The "New Horizons Forum" is a full day of presentations, panels, and discussions featuring CEOs from start-up companies, industry executives, ophthalmic leaders, venture capitalists, and FDA directors. It is the centerpiece event of the three-day Glaucoma 360.
Who: Jeffrey L. Cleland, PhD, GrayBug Interim Chief Executive Officer
When: 11:48 am, Friday, January 29, 2016
Where: Palace Hotel, 2 New Montgomery Street, San Francisco, CA
About GrayBug, Inc.
GrayBug is developing injectable controlled release technologies to reduce the frequency of ocular therapy to twice per year. The feasibility of this technology has been validated in animals with the company's lead program, GB-102. A therapy targeting VEGF and PDGF pathways. GB-102 has the potential for treating patients with neovascular (wet) AMD just twice a year, compared to 12-15 times a year with the currently available drugs. These technologies have solved the problems with tolerability and blockage of vision noted with many injectable sustained release ocular products and are also being developed for twice per year treatment of glaucoma.
GrayBug was founded as a spin-out of the Wilmer Eye Institute of the Johns Hopkins University School of Medicine. GrayBug's technologies were co-developed by GrayBug founder, Justin Hanes, PhD, who is the Lewis J. Ort Professor of Ophthalmology at the Wilmer Eye Institute of the Johns Hopkins University, in collaboration with GrayBug cofounders, and leading ophthalmology clinician-scientists from the Wilmer Eye Institute Peter A. Campochiaro, MD, and Peter J. McDonnell, MD. The technologies were exclusively licensed from Johns Hopkins University. For more information, please visit www.graybug.com.
Who: Jeffrey L. Cleland, PhD, GrayBug Interim Chief Executive Officer
When: 11:48 am, Friday, January 29, 2016
Where: Palace Hotel, 2 New Montgomery Street, San Francisco, CA
About GrayBug, Inc.
GrayBug is developing injectable controlled release technologies to reduce the frequency of ocular therapy to twice per year. The feasibility of this technology has been validated in animals with the company's lead program, GB-102. A therapy targeting VEGF and PDGF pathways. GB-102 has the potential for treating patients with neovascular (wet) AMD just twice a year, compared to 12-15 times a year with the currently available drugs. These technologies have solved the problems with tolerability and blockage of vision noted with many injectable sustained release ocular products and are also being developed for twice per year treatment of glaucoma.
GrayBug was founded as a spin-out of the Wilmer Eye Institute of the Johns Hopkins University School of Medicine. GrayBug's technologies were co-developed by GrayBug founder, Justin Hanes, PhD, who is the Lewis J. Ort Professor of Ophthalmology at the Wilmer Eye Institute of the Johns Hopkins University, in collaboration with GrayBug cofounders, and leading ophthalmology clinician-scientists from the Wilmer Eye Institute Peter A. Campochiaro, MD, and Peter J. McDonnell, MD. The technologies were exclusively licensed from Johns Hopkins University. For more information, please visit www.graybug.com.